Innate Pharma investor conference call on November 14, 2016 to discuss recent new clinical data
Marseille, November 10, 2016
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announces that the Company will host a conference call for institutional investors and sell-side analysts to discuss recent clinical data on November 14, 2016.
During the conference call, the Company's management team will discuss lirilumab and IPH4102 clinical data published at the most recent scientific meetings:
***INVESTOR CALL FOR RECENT NEW CLINICAL DATA***
The call will be held on November 14, 2016 at 8:00 am ET (2 pm CET)
Dial in numbers:
USA: +1 855 402 77 62
International: +33 (0) 1 70 77 09 34
Hervé Brailly, Chief Executive Officer of Innate Pharma
Nicolai Wagtmann, Chief Scientific Officer of Innate Pharma
Pierre Dodion, Chief Medical Officer of Innate Pharma
Jan B. Vermorken, Emeritus Professor of Oncology, University of Antwerp, Belgium
The slideshow of the presentation will be made available on the Company's website 15 minutes before the call begins.
A replay will be available following the call on Innate Pharma's website.
About the latest and upcoming presentations:
Lirilumab (anti-KIR antibody), partnered with Bristol-Myers Squibb:
IPH4102 (anti-KIR3DL2 antibody):
Monalizumab (anti-NKG2A antibody), partnered with AstraZeneca/Medimmune:
About Innate Pharma:
Innate Pharma S.A. is a clinical-stage biotechnology company with a focus on discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients.
Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells.
The Company's aim is to become a commercial stage biopharmaceutical company in the area of immunotherapy and focused on serious unmet medical needs in cancer. Innate Pharma has pioneered the discovery and development of checkpoint inhibitors to activate the innate immune system. Innate Pharma's innovative approach has resulted in three first-in-class, clinical-stage antibodies targeting natural killer cell receptors that may address a broad range of solid and hematological cancer indications as well as additional preclinical product candidates and technologies. Targeting receptors involved in innate immunity also creates opportunities for the Company to develop therapies for inflammatory diseases.
The Company's expertise and understanding of natural killer cell biology have enabled it to enter into major alliances with leaders in the biopharmaceutical industry including AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi.
Based in Marseille, France, Innate Pharma has more than 140 employees and is listed on Euronext Paris.
Learn more about Innate Pharma at www.innate-pharma.com .
Practical Information about Innate Pharma shares:
This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website or on Innate Pharma's website.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
For additional information, please contact:
|Innate Pharma||Press Contacts|
Director, Investor Relations
ATCG Press (France)
|Tel.: +33 (0)4 30 30 30 87||Mob: +33 (0)6 10 54 36 72|
|Consilium Strategic Communications (ROW)|
Mary-Jane Elliott / Sue Stuart /
Jessica Hodgson / Hendrik Thys / Cameron Standage
|Tel.: +44 (0)20 3709 5700|
[*] Society for Immunotherapy of Cancer's (SITC) 2016 Annual Meeting (November 9-13, 2016)
[**] European Society for Medical Oncology (ESMO) 2016 congress (October 7 - 11, 2016)
[***] Third World Congress of Cutaneous Lymphomas (3WCCL) (October 26-28, 2016)InnInvestor conference call on November 14, 2016
Last updated on: 11/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.